19094-Urothelial Cancer-NA-564

Urothelial Cancer

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number:

  • Address

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

Search by practice name, trial titles, indicators and specific disease types.